Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

THOUSAND OAKS, Calif., June 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the completion of patient enrollment in the FOURIER outcomes trial designed to evaluate whether treatment with RepathaTM (evolocumab) in combination with statin therapy compared to placebo plus statin therapy reduces the risk of recurrent cardiovascular events in patients with high cholesterol and clinically evident cardiovascular disease. Results from the approximately 27,500-patient FOURIER study are expected no later than 2017.



Amgen - Investors - RSS Content